NCT/Study#
NCT03229200 /
PCYC-1145-LT
Extended Treatment Protocol For Subjects Continuing To Benefit From Ibrutinib After Completion Of Ibrutinib Clinical Trials
DISEASE GROUP:
Lymphoma
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
